| Company Name: |
Sigma-Aldrich |
| Tel: |
021-61415566 800-8193336 |
| Email: |
orderCN@merckgroup.com |
|
| Product Name: | C3, HUMAN | | Synonyms: | COMPLEMENT 3, HUMAN;COMPLEMENT C3, HUMAN;C3, HUMAN;COMPLEMENT C3 FROM HUMAN SERUMFROZEN SOL UTION;complement c3 from human serum;C3 Protein;COMPLEMENT C3 | | CAS: | 80295-41-6 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![C3, HUMAN Structure]() |
| | C3, HUMAN Chemical Properties |
| storage temp. | -70°C | | form | lyophilized powder | | biological source | human | | Specific Activity | ≥3000C3H50 units/mg (using C3 deficient serum) |
| Hazard Codes | B | | WGK Germany | 3 | | Storage Class | 10 - Combustible liquids |
| | C3, HUMAN Usage And Synthesis |
| Uses | Complement C3 is important in complement activation through the classical and alternative pathways. Complement C3 has been used in studies of bacterial defense against the complement system. Research on streptococcus infection has shown that Streptococcal pyrogenic exotoxin B (SPE B), a cysteine protease, can prevent phagocytic activity via cleavage of the C3 and impairing the pathways of the compliment system. C3 deficiency can result in recurrent infections and immune complex disorders. Recent research has shown that inherited C3 deficiency can occur either through homozygous mutations or through compound heterozygous mutations, | | Biochem/physiol Actions | Complement C3 is the third and most abundant component of the complement pathway. It plays a central role in complement activation, being involved in both the classical and alternative pathways. C3 or its proteolytic fragments mediate many biological functions such as opsonization and anaphylatoxin activities. Pro-C3 is synthesized as a large single chain of 185 kDa and is processed to a disulfide-linked heterodimer consisting of an α-chain (115 kDa) and a β-chain (70 kDa) in the plasma. C3 is cleaved by the C3 convertases in either pathway (C4b2a, C3iBb, C3bBb) to C3b (176 kDa) comprised of the large C-terminal portion of the α-chain and the β-chain. C3b interacts with other complement components to initiate the amplification cascade. Studies of C3 function have been facilitated by experimentally induced C3 deficiency in animals by injection of cobra venom factor and more recently with gene ablation technology. | | Description | Human Complement C3 produced in Human plasma having a molecular mass of 185 kDa. | | Source | Human Plasma | | Background | Native human C3 is a naturally glycosylated polypeptide containing two disulfide-linked chains. C3 is central to the activation of all 3 pathways of complement activation. Initiation of each pathway generates proteolytic enzyme complexes which binds the target surface. These enzymes cleave a peptide bond in C3 releasing the anaphylatoxin C3a and activating C3b. Most of the C3 activated during complement activation never attaches to the surface due to its thioester reaction with water forming fluid phase C3b which is rapidly inactivated by factors H and I forming iC3b. Surface-bound C3b is necessary in all 3 pathways for efficient activation of C5 and formation of C5b-9 complexes that lyse the target cell membrane. |
| | C3, HUMAN Preparation Products And Raw materials |
|